Clinical Trial Update: A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML [Phase 2]

View source ↗

Summary

This Phase II randomized trial evaluates whether monitoring trough plasma levels of imatinib improves treatment management in patients with newly diagnosed chro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 2 | Status: COMPLETED